Symptomatic Necrosis With Antibody-Drug Conjugates and Concurrent Stereotactic Radiotherapy for Brain Metastases
Cette étude analyse l'association entre un traitement par conjugué anticorps-médicament et le risque de radionécrose symptomatique liée à une radiochirurgie chez des patients présentant des métastases cérébrales
Stereotactic radiotherapy (SRT) is an essential treatment modality for patients with brain metastases (BrM), but some patients develop radiation necrosis (RN). As antibody-drug conjugates (ADCs) have demonstrated intracranial efficacy, we investigated whether BrM SRT with concurrent ADC therapy may be associated with increased risk of symptomatic RN (SRN).
JAMA Oncology 2023